129 related articles for article (PubMed ID: 32268017)
1. Development of a 1-year risk-prediction nomogram for good functional response with anti-VEGF agents in naive diabetic macular oedema.
Gabrielle PH; Massin P; Arnould L; Couturier A; Bouché-Pillon J; Maupin E; Aho-Glele S; Bron AM; Kodjikian L; Creuzot-Garcher C
Acta Ophthalmol; 2020 Dec; 98(8):e975-e982. PubMed ID: 32268017
[TBL] [Abstract][Full Text] [Related]
2. Retinal Layers Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Anti-VEGF Agents: Long-Term Outcomes of a Spectral-Domain OCT Study.
Chatziralli I; Kazantzis D; Theodossiadis G; Theodossiadis P; Sergentanis TN
Ophthalmic Res; 2021; 64(2):230-236. PubMed ID: 32564022
[TBL] [Abstract][Full Text] [Related]
3. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
4. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
[TBL] [Abstract][Full Text] [Related]
5. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
[TBL] [Abstract][Full Text] [Related]
6. Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema.
Felfeli T; Juncal VR; Hillier RJ; Mak MYK; Wong DT; Berger AR; Kohly RP; Kertes PJ; Eng KT; Boyd SR; Altomare F; Giavedoni LR; Muni RH
Am J Ophthalmol; 2019 Oct; 206():176-183. PubMed ID: 30959004
[TBL] [Abstract][Full Text] [Related]
7. Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy.
Mikhail M; Stewart S; Seow F; Hogg R; Lois N
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1411-1418. PubMed ID: 29779188
[TBL] [Abstract][Full Text] [Related]
8. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
[TBL] [Abstract][Full Text] [Related]
9. Prediction of response to anti-vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography-based machine learning method.
Cao J; You K; Jin K; Lou L; Wang Y; Chen M; Pan X; Shao J; Su Z; Wu J; Ye J
Acta Ophthalmol; 2021 Feb; 99(1):e19-e27. PubMed ID: 32573116
[TBL] [Abstract][Full Text] [Related]
10. Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity.
Busch C; Okada M; Zur D; Fraser-Bell S; Rodríguez-Valdés PJ; Cebeci Z; Lupidi M; Fung AT; Gabrielle PH; Giancipoli E; Chaikitmongkol V; Laíns I; Santos AR; Kunavisarut P; Sala-Puigdollers A; Chhablani J; Ozimek M; Hilely A; Degenhardt V; Loewenstein A; Iglicki M; Rehak M;
Acta Ophthalmol; 2020 Nov; 98(7):e801-e806. PubMed ID: 32115886
[TBL] [Abstract][Full Text] [Related]
11. Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response.
Lee J; Moon BG; Cho AR; Yoon YH
Ophthalmology; 2016 Nov; 123(11):2368-2375. PubMed ID: 27613201
[TBL] [Abstract][Full Text] [Related]
12. The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF.
Chang CK; Cheng CK; Peng CH
Eye (Lond); 2017 May; 31(5):762-770. PubMed ID: 28106889
[TBL] [Abstract][Full Text] [Related]
13. Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study.
Shimura M; Kitano S; Muramatsu D; Fukushima H; Takamura Y; Matsumoto M; Kokado M; Kogo J; Sasaki M; Morizane Y; Kotake O; Koto T; Sonoda S; Hirano T; Ishikawa H; Mitamura Y; Okamoto F; Kinoshita T; Kimura K; Sugimoto M; Yamashiro K; Suzuki Y; Hikichi T; Washio N; Sato T; Ohkoshi K; Tsujinaka H; Kusuhara S; Kondo M; Takagi H; Murata T; Sakamoto T;
Br J Ophthalmol; 2020 Sep; 104(9):1209-1215. PubMed ID: 31784500
[TBL] [Abstract][Full Text] [Related]
14. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
15. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.
Hatz K; Ebneter A; Tuerksever C; Pruente C; Zinkernagel M
Ophthalmologica; 2018; 239(4):205-214. PubMed ID: 29402873
[TBL] [Abstract][Full Text] [Related]
16. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
[TBL] [Abstract][Full Text] [Related]
17. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections.
Cetin EN; Demirtaş Ö; Özbakış NC; Pekel G
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1801-1806. PubMed ID: 29922890
[TBL] [Abstract][Full Text] [Related]
18. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema.
Cicinelli MV; Cavalleri M; Querques L; Rabiolo A; Bandello F; Querques G
Br J Ophthalmol; 2017 Dec; 101(12):1689-1693. PubMed ID: 28432109
[TBL] [Abstract][Full Text] [Related]
19. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.
Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS
Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365
[TBL] [Abstract][Full Text] [Related]
20. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
